Business Context and Reporting Period
This Form 8-K was filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp) on April 10, 2020, reporting events occurring on April 6, 2020. The company is incorporated in Delaware and trades on the NASDAQ under the symbols HJLI (Common Stock) and HJLIW (Warrants).
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on a corporate governance event.
Material Changes
The primary material change reported is the appointment of Craig Glynn as Interim Chief Financial Officer and Interim Treasurer by the Board of Directors on April 6, 2020.
- Compensation: Mr. Glynn will receive $10,000 per month for his services.
- Background: Mr. Glynn, age 59, has over 35 years of financial experience, including founding Edward Thomas Associates and serving as CFO for various technology and manufacturing firms.
- Relationships: No family relationships exist between Mr. Glynn and other directors or officers, and no undisclosed arrangements influenced his selection.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a standard disclosure of an officer appointment.
Investor Verification Checklist
- Verify the departure of the previous CFO (if applicable) to understand the context of the interim appointment.
- Confirm the trading status of HJLI and HJLIW on the NASDAQ.
- Review subsequent filings to determine if the interim CFO role becomes permanent or if a permanent successor is named.
- Note the discrepancy between the requested company name (Envveno Medical Corp) and the actual registrant (Hancock Jaffe Laboratories, Inc.).